EHPC Completed Trials

Title

NIHR ref

RLBUHT

RD&I

LSTM

RD&I

REC

EudraCT 
number:

Primary objective

Where Archived

Funder

EHPC: The effect of age on immune function

 20792  5174  15-053 16/NW/0031 Detection of S. pneumoniae by classical bacteria culture methods from one or more nasal wash sample in the first 14 days following initial pneumococcal challenge.   MRC

EHPC: The effect of asthma on immune response to Pneumococcus

Started 2016

20857 5173 16-010 16/NW/0124

To determine the rate of EHPC acquisition in people with asthma 

To study the systemic and mucosal immune responses

To determine the protective effect of carriage against reacquisition of carriage

   MRC
EHPC:  Hand to nose transmission of streptococcus pneumoniae in healthy participants – pilot study

Started 2017  33503

 33503 5376   16-069  17/NW/0054 To determine the feasibility of Experimental Pneumococcal Carriage acquisition following pneumococcal transmission from hand to nostrils.    

MRC

and

Pharma:

EHPC: Hand Wash Study

Started 2017

  N/A  
17-077
 17/NW/0658 To evaluate if hand washing with antimicrobial soap affects hand to nose transmission of Streptococcus pneumoniae leading to nasal colonisation    

Pharma:

Unilever

Testing new strains in the EHPC Model

Started 2017  20815

  5124 15-051  15/NW/0931 To establish experimental human carriage with a non-vaccine and 23F serotype pneumococcus.

To determine the protective effect of carriage against reacquisition of carriage following inoculation with a different pneumococcal strain.

   MRC

EHPC The Effect of Live Attenuated Influenza Vaccine (LAIV) on EHPC

Started 2016

18994

4896

14-058

14/NW/1460

 

EudraCT

2014-004634-26

To define the effect of LAIV on pneumococcal colonisation using the EHPC model in order to assess the potential effects of mass influenza vaccination. We will measure colonisation acquisition, density and duration.

 

MRC and Gates Foundation

EHPC Pilot study of repeated mucosal sampling on experimental human pneumococcal colonization

Started 2015

 

4938

15-027

15/NW/0146

To evaluate if repeated mucosal sampling will obtain sufficient tissue for immunological assessment.

 

 

 

Genocea (phase 2)  pneumococcal otitis media vaccine

Started 2014

17331

4741

14-058

14/NW/0355

To evaluate the effect of Gen-004 on pneumococcal colinazation compared to placebo.

RLBUHT

Pharma: GENOCEA

PCV EHPC

Started 2013

13932

4431

 

12/NW/0873

 

EudraCT

2012-005141-20

To evaluate the effect of PCV on pneumococcal colonization compared to Hep A vaccine (Avaxim).

 

Gates Foundation

Dose ranging and reproducibility

Started 2011

11731

4210

 

11/NW/0592

To establish >40% pneumococcal colonization using 6B and 23F creating a dose range curve and to validate the model by reproducing the findings.

 

BM Gates Foundation